Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05901636 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults
A Phase 1 study, sponsored by Janssen Vaccines & Prevention B.V..
- Completed
- Registry status
- Phase 1
- Development phase
- 170
- Enrollment target
NCT05901636 is a Phase 1 study that has completed, run by Janssen Vaccines & Prevention B.V.. The registered enrollment target is 170 participants.
The verdict
NCT05901636, a Phase 1 study, has completed, sponsored by Janssen Vaccines & Prevention B.V..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 170 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate safety/ reactogenicity of INFLUENZA G1 mini-hemagglutinin stem-derived protein vaccine antigen (mHA), with or without Al(OH)3 adjuvant, in healthy adults greater than or equal to (\>=) 18 to less than or equal to (\<=) 45 years of age.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL INFLUENZA G1 mHA
- BIOLOGICAL Al(OH)3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2023-05-17 |
| Est. Completion | 2024-08-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05901636
The ClinicalTrials.gov registry entry for NCT05901636 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Vaccines & Prevention B.V., which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05901636 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05901636 about?
NCT05901636 is a clinical study titled "A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults". The primary purpose of this study is to evaluate safety/ reactogenicity of INFLUENZA G1 mini-hemagglutinin stem-derived protein vaccine antigen (mHA), with or without Al(OH)3 adjuvant, in healthy adults greater than or equal to (\>=) 18 to less than or equal to (\<=) 45 years of age.
What is the current status of trial NCT05901636?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 170 participants. The study started on 2023-05-17. Estimated completion is 2024-08-19.
What interventions are being tested in trial NCT05901636?
The interventions under investigation include: Placebo (BIOLOGICAL), INFLUENZA G1 mHA (BIOLOGICAL), Al(OH)3 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05901636?
This trial is sponsored by Janssen Vaccines & Prevention B.V., which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.